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Background & aims: It has been suggested that anabolic resistance, or a blunted protein synthetic
response to anabolic stimuli, contributes to the failure of muscle mass maintenance in older adults. The
amino acid leucine is one of the most prominent food-related anabolic stimuli. However, data on muscle
protein synthesis (MPS) after administration of a single bolus of leucine in aged populations is lacking
and long-term single leucine supplementation has not been shown to increase muscle mass. This study
aimed to determine the MPS response to the administration of a single bolus of leucine or to leucine
combined with whey protein, in aged mice.
Methods: Overnight fasted C57/BL6RJ mice at 25-mo of age received an oral gavage with leucine or
whey-protein enriched with leucine (0.75 g/kg bodyweight total leucine in both) or 0.5 mL water (fasted
control). Subsequently, mice were s.c. injected with puromycin (0.04 mmol/g bw at t ¼ 30, 45 or 60 min)
and were sacriﬁced 30 min thereafter. Amino acid concentrations were determined in plasma and right
muscle tibialis anterior (TA). Left TA was used to analyse MPS by SUnSET method and phosphorylation
rate of Akt, 4E-BP1 and p70S6k by western blot.
Results: In aged mice, leucine administration failed to increase MPS, despite a 6-fold increase in plasma
leucine and elevated muscle free leucine levels (P < 0.05). In contrast, leucine-enriched whey protein
signiﬁcantly stimulated MPS in aged mice at 60 min after gavage (P < 0.05). Muscle free EAA, NEAA and
the phosphorylation rate of Akt, 4E-BP1 and p70S6k increased signiﬁcantly (P < 0.05), only after
administration of leucine-enriched whey protein.
Conclusions: MPS is stimulated in aged mice by leucine-enriched whey protein but not by leucine
administration only. Administration of other amino acids may be required for leucine administration to
stimulate muscle protein synthesis in aged mice.
© 2018 Nutricia Research. Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition
and Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).; EAA, essential amino acid;
tein synthesis; NEAA, non-
, western blot.
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Skeletal muscle mass is the result of a balance between protein
synthesis and protein breakdown of skeletal muscle proteins. With
ageing, changes in muscle protein turnover may lead to a decline in
skeletal muscle mass and decreased muscle strength and physical
endurance [1e3]. This process ultimately leads to a muscle wasting
condition known as sarcopenia [4]. The diminished proteinciety for Clinical Nutrition and Metabolism. This is an open access article under the
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from a meal [5], known as anabolic resistance, has been suggested
to contribute to the inability to maintain muscle mass in older in-
dividuals [6]. Therefore, many research groups are now trying to
ﬁnd effective strategies to overcome the higher anabolic threshold
associated with aging [7] in order to prevent and treat muscle mass
loss in this population.
One of the strategies is related to the branched chain amino acid
leucine, which is unique in its ability to activate mTORC1 and its
downstream phosphorylation of p70S6k and 4E-BP1. Both factors
are involved in mRNA translation initiation and de novo muscle
protein synthesis (MPS) [8e10]. Moreover, leucine is an insulino-
tropic amino acid and insulin can affect protein metabolism
(reviewed in Ref. [11]). Leucine ingestion has been shown to
effectively stimulate MPS in young rat skeletal muscle at single oral
doses ranging between 0.135 and 1.35 g kg1 bw [12]. A dose-
dependent relationship between leucine and MPS was also
observed when isolatedmuscles fromyoung rats were incubated in
an organ bath with various leucine concentrations [13].
Studies in aged rats conﬁrm the presence of anabolic resistance
to leucine when administered as a single amino acid in an organ
bath [13], but we are not aware of in vivo studies with orally
administered leucine, not in combination with other nutrients, in
aged animals. However, there are reports that leucine-enrichment
of a protein meal can effectively stimulate MPS in vivo in old rats
[13e15]. This observation is similar to what we might ﬁnd in older
adults whose attenuated MPS response can be reversed by
increasing the proportion of leucine in an EAA mixture [16] or by
adding leucine to a bolus of intact proteins [17e19]. While leucine-
enriched amino acid mixtures or proteins can stimulate MPS, the
effect of leucine alone on MPS is less well studied in the aged
population. This is relevant, since long-term oral supplementation
of leucine as standalone intervention, provided with meals, has not
been proven effective in preventing muscle wasting or in increasing
muscle mass in older adults (reviewed in Refs. [20,21]). Therefore,
further understanding of the MPS response to leucine administra-
tion in the ageing population is needed to deﬁne the most effective
strategy.
The objective of our study was to investigate the effect of
leucine, either as a single amino acid or in the context of a leucine-
enriched whey protein gavage, on MPS and activation of the mTOR
signalling pathway in aged mice. MPS was measured at different
time points (60, 75 and 90min postprandial) to explore if aged C57/
BL6Jmice showa delay in the anabolic response. In a previous study
we showed anabolic resistance to a leucine-enriched whey protein
gavage in these aged mice (compared with adult mice) that could
be overcome by increasing the total amount of protein in the
gavage [22]. To further understand the relevance of leucine and
availability of other amino acids, we measured plasma and muscle
free amino acid concentrations. Additionally, we measured plasma
concentrations of insulin and glucose.
2. Methods
2.1. Animals
Aged male C57/BL6J mice of 25 months of age were obtained
from Janvier Labs (Saint Berthevin, France). Animals were individ-
ually housed in a climate-controlled room (12:12 darkelight cycle
(lights on: 7 a.m.) with a constant room temperature of 21 ± 1 C).
Housing consisted of Makrolon Type III cages (Tecniplast, Italy)
with bedding and tissues. Mice were fed ad libitumwith a standard
diet (AIN93M) and had free access to tap water. All experimental
procedures were approved by an Animal Ethical Committee (DEC
consult, Soest, the Netherlands) and complied with the principlesof good laboratory animal care following the European Directive for
the protection of animal used for scientiﬁc purposes. The animals
were cared for according to the NIH Guide for the Care and Use of
Laboratory Animals. Upon arrival, the mice were allowed to accli-
matize for 2 weeks and were fasted overnight before section. At the
day of section, mice were randomized to 3  3 groups with no
greater deviation than 5% from the overall mean bodyweight (n¼ 8
per group). To investigate a delay in anabolic response, three in-
tervals were studied (60, 75 and 90 min) and per time point 3
groups were analysed (fasted, single leucine or leucine-enriched
whey protein).
2.2. In vivo muscle protein synthesis
MPS was measured with the SUnSET method as previously
described by Goodman et al. [23] and previously used by us [22,24].
The SUnSET method is an alternative method to determine MPS
compared to radioactive isotope or stable isotope tracers. Goodman
et al. [23] validated the SUnSET method with a 3H-phenylalanine
ﬂooding method in ex vivo plantaris muscle from mice that had
received synergist ablation (SA). The results showed that the SUn-
SET technique was indistinguishable from a standard radioactive-
based or a standard stable isotope incorporation technique in
detecting SA-induced increases in protein synthesis. In addition, in
our previous study [24], protein synthesis was measured in myo-
tubes after a 50 min incubation with L-[1-13C]valine by measuring
tracer enrichment, or a 30 min incubation with puromycin by
quantifying incorporation of puromycin into peptides. Results of
both methods were comparable. Furthermore, we used this tech-
nique successfully in a previous study were similar dosages of
protein showed an anabolic response in adult mice [22]. This proves
the reliability of the SUnSET method. This method also made it
possible to determine protein synthesis rate and activation of key
signalling pathways involved in this process using the same
experimental samples.
At section day, mice received an oral gavage (end volume
0.5 mL) containing either 18.8 mg leucine (LEU) (Sigma Aldrich)
(0.75 g/kg bodyweight) or 139 mg leucine-enriched whey protein
isolate (WHEY þ LEU) (Lacprodan 9224, Arla Foods) (5.56 g/kg
bodyweight whey protein with total leucine content of 18.8 mg
leucine or 0.75 g/kg bodyweight). Concentrations were based on a
nutritional supplement (containing 20 g whey protein and 2.8 g
total leucine per serving) that was studied in older adults for its
effect on MPS [25]. Amounts of whey protein and leucine were
subsequently translated to the mouse setting: ratio of daily food
consumption of a mouse and a bolus intake. The postprandial
condition is compared with the fasting state (0.5 mL tap water) to
indicate the levels of postprandial increase. Thirty, 45 or 60 min
after oral gavage adult mice received a s.c. injectionwith 0.04 mmol/
g bodyweight puromycin (Calbiochem) [23]. After an additional
30 min, mice were euthanized by cardiac puncture under total
isoﬂurane anaesthesia (isoﬂurane/N2O/O2). As a result, MPS was
measured after a 60, 75 and 90 min postprandial period. Plasma
and serum samples were prepared by centrifugation and hind limb
muscles were excised, weighted, frozen in liquid nitrogen and
stored at 80 C until analysis.
2.3. Western blot analysis
Left tibialis anteriormuscles were cut into pieces and WB buffer
(40 mM Tris pH 7.5; 1 mM EDTA; 5 mM EGTA; 10% glycerol; 1%
Triton X-100; PhosSTOP Phosphatase Inhibitor Cocktail (Roche Di-
agnostics) and Protease Inhibitor Ultra Tablets (Roche Diagnostics),
1 tablet per 10 mL buffer) was added in a ratio of 10 ml/mg muscle.
Muscles were homogenized using a FastPrep-24 (MP Biomedicals)
F.J. Dijk et al. / Clinical Nutrition ESPEN 24 (2018) 127e133 129with 3 chrome-steel beads per tube and run 3 times for 30 s on
6.5 m/s speed. Between rounds, tubes were placed on ice to prevent
heating of the samples. Subsequently, samples were continuously
shaken at 4 C for 1 h. Protein content was determined using the
BCA protein assay kit (Pierce). Muscle homogenates were dissolved
in Laemmli buffer (BioRad) and 20e35 mg was loaded on a 4e15%
gradient gel (Criterion TGX Precast Gels, BioRad). For each experi-
ment, a pool of the homogenates of mice in fasting state was made
and loaded in threefold on each gel to be able to compare samples
from different gels. Electrophoresis was performed at 100 V. Pro-
teins were transferred to a 0.2 mm PVDF membrane (BioRad).
Membranes were blocked with 5% Protifar protein powder (Nutri-
cia) in TBST buffer (25 mM Tris, pH 7.6; 150 mM NaCl; 0.1% Tween-
20) for 1 h followed by overnight incubation at 4 C with anti-
puromycin antibody (clone 12D10, 1:5000, Merck Millipore) in 1%
BSA in TBST. For mTOR pathway proteins, membranes were incu-
bated with Akt (1:1000); phospho-Akt (Ser473, 1:3000); 4E-BP1
(1:1000); phospho-4E-BP1 (Ser65, 1:1000); p70S6K (1:1000) and
phospho-p70S6K (Thr421/Ser424, 1:1000), all purchased from Cell
Signalling Technology. Membranes were washed 4 times in TBST
and incubated for 1 h at room temperature with HRP-conjugated
anti-mouse IgG-Fc2a antibody (1:50.000, Jackson ImmunoR-
esearch) for anti-puromycin antibody or HRP-conjugated anti-
rabbit IgG (1:1000, Cell Signaling Technology) for pathway anti-
bodies. After 4 times washing with TBST, membranes were incu-
bated for 5 min with ECL substrate (SuperSignal West FEMTO,
Pierce). Protein synthesis was determined by the density of the
whole lane using a Chemidoc XRS (BioRad) and calculated as a
relative ratio to the fasted control group. mTOR pathway proteins
were determined by the density of the speciﬁc band representing
the phosphorylated or total protein as indicated by the supplier.
After analysis, blots were stained with Coomassie Brilliant Blue R-
250 (BioRad) for 30 min and destained in destain solution (10%
acetic acid, 40% methanol) to correct for protein loading differences
between lanes.2.4. Biochemical measurements
Right tibialis anterior muscle was freeze dried, homogenised in
2% perchloric acid, centrifuged (2000 g for 20 min at 4 C) and
supernatants were used to determine muscle free amino acid
concentrations. Muscle free and plasma amino acid concentrations
were measured using ultra-fast liquid chromatography (UFLC) [26].
Serum glucose levels were determined using an enzymatic col-
ourimetric method (GOD-PAP method, Roche Diagnostics) [27].
Serum insulin was analysed by ELISA assay (10-1247-01 Mercodia
AB) [26].Fig. 1. The effect of leucine and leucine-enriched whey protein on plasma leucine (A) and
leucine; W, leucine-enriched whey. Values are means ± SEM. ‘a’ P < 0.05 vs F same time; ‘2.5. Statistical analysis
All data are expressed as means ± SEM. Statistical analyses were
performed using IBM SPSS Statistics (version 19; SPSS Inc, Chicago,
IL). Univariate ANOVA followed by LSD post hoc analysis was used to
compare groups. Data fromWB pathway protein 4E-BP1 showed no
normal distribution; therefore, all WB data were tested using uni-
variate ANOVA followed by LSD post hoc analysis after log-
transformation of the data. Statistical signiﬁcance is deﬁned as
P < 0.05.3. Results
3.1. Amino acid concentrations in plasma and TA muscle
Plasma leucine concentrations increased 6-fold at 60 and 75min
after LEU supplementation and 9-fold after 90 min of LEU (P < 0.05
for 60, 75 and 90 min vs fasted at same time point; Fig. 1A, Table 1).
With WHEY þ LEU, plasma leucine concentrations increased 7-fold
after 60min and 4-fold after 75min (P < 0.05 vs fasted at same time
point). Plasma concentrations of isoleucine did not change with
LEU but increased 7-fold, 4-fold and 3-fold withWHEYþ LEU at 60,
75 and 90 min respectively (P < 0.05 vs fasted at same time point;
Table 1). Plasma valine increased 2-fold with LEU at 90 min vs
fasted at same time point, and increased 5-fold, 3-fold and 3-fold
with WHEY þ LEU at 60, 75 and 90 min respectively (P < 0.05 vs
fasted at same time point; Table 1). Plasma EAA concentrations
(without leucine) increased 2-fold after LEU supplementation
compared to the fasted group after 75 and 90min (P < 0.05), but not
after 60 min (Table 1). With WHEY þ LEU, plasma EAA concen-
trations increased 5-fold after 60 min and 3-fold after 75 and
90 min (P < 0.05 vs fasted at same time point; Table 1). Plasma
NEAA increased 2-fold with LEU at 75 and 90min (P < 0.05 vs fasted
at same time point) but did not change after 60 min. With
WHEY þ LEU supplementation, plasma NEAA increased 2.5-fold
after 60 min (P < 0.05 vs fasted at same time point) but did not
change after 75 and 90 min.
Free leucine concentrations in muscle increased in all inter-
vention groups compared to the group that fasted at all post-
prandial times (P < 0.05 vs fasted at same time point, Fig. 1B;
Table 1). Muscle free isoleucine concentrations increased 4-fold at
60 min, 2.5-fold at 75 min and 2-fold at 90 min after gavage with
WHEYþ LEU (P < 0.05 vs fasted at same time point, Table 1) but did
not change after LEU gavage. Muscle free valine concentrations
increased 2.7-fold at 60 and 75 min and 2.4-fold at 90 min after
gavage with WHEY þ LEU (P < 0.05 vs fasted at same time point,
Table 1), also no signiﬁcant changes were observed after LEUmuscle free leucine concentrations (B) at 60, 75 or 90 min after gavage. F, fasted; L,
b’ P < 0.05 vs same supplementation but other time; ‘c’ P < 0.05 vs LEU at same time.
Table 1
Plasma and muscle glucose, insulin and plasma andm. TA free amino acid concentrations at 60, 75 and 90 min after oral gavage of leucine or leucine-enriched whey protein in
aged mice.
60 min 75 min 90 min
Fasted Leu Whey þ Leu Fasted Leu Whey þ Leu Fasted Leu Whey þ Leu
n 8 8 7 8 7 8 8 7 8
Blood concentrations
Glucose (g/L) 0.9 ± 0.2 0.9 ± 0.2 0.6 ± 0.1 1.0 ± 0.2 1.4 ± 0.3b 0.6 ± 0.2 1.0 ± 0.2 1.3 ± 0.2 0.4 ± 0.1a
Insulin (mg/L) 0.7 ± 0.2 2.2 ± 0.5a 1.1 ± 0.2 0.6 ± 0.1 1.5 ± 0.4ab 0.8 ± 0.1 0.4 ± 0.0 1.4 ± 0.1ab 0.8 ± 0.2
Leucine (mmol/L) 187 ± 13 1081 ± 137a 1362 ± 143a 211 ± 10 1325 ± 251a 854 ± 123a 230 ± 19 2119 ± 719abd 833 ± 103d
ILE (mmol/L) 109 ± 6 125 ± 22 747 ± 73ad 122 ± 6 138 ± 23 473 ± 67abd 129 ± 11 190 ± 49 425 ± 54abd
VAL (mmol/L) 198 ± 10 269 ± 38 1077 ± 77ad 232 ± 18 315 ± 47 794 ± 97abd 233 ± 17 402 ± 90a 765 ± 81abd
EAA (mmol/L) 824 ± 34 1219 ± 140 4004 ± 296ad 948 ± 87 1534 ± 219a 2700 ± 262abd 954 ± 65 2032 ± 442ab 2530 ± 257ab
NEAA (mmol/L) 1017 ± 56 1434 ± 117 2543 ± 253ad 1170 ± 190 2177 ± 370ab 1821 ± 172b 1218 ± 98 2595 ± 593ab 1786 ± 136bd
Muscle free concentrations
Leucine (mmol/g dw) 0.7 ± 0.0 3.7 ± 0.4a 2.9 ± 0.3a 0.8 ± 0.0 3.5 ± 0.5a 2.5 ± 0.3ad 0.9 ± 0.1 3.7 ± 0.6a 2.3 ± 0.3ad
ILE (mmol/g dw) 0.4 ± 0.0 0.4 ± 0.0 1.5 ± 0.2ad 0.5 ± 0.0 0.3 ± 0.0 1.3 ± 0.2ad 0.5 ± 0.1 0.3 ± 0.1 1.1 ± 0.2abd
VAL (mmol/g dw) 0.9 ± 0.0 0.9 ± 0.1 2.4 ± 0.2ad 0.9 ± 0.1 0.8 ± 0.1 2.3 ± 0.2ad 0.9 ± 0.1 0.8 ± 0.1 2.2 ± 0.2ad
EAA (mmol/g dw) 12.3 ± 0.2 12.3 ± 0.1 16.1 ± 0.5ad 12.5 ± 0.2 11.7 ± 0.2 15.9 ± 0.5ad 12.4 ± 0.3 12.0 ± 0.3 15.3 ± 0.7ad
NEAA (mmol/g dw) 25.3 ± 0.7 27.7 ± 0.7 29.4 ± 0.9a 25.0 ± 1.3 27.5 ± 0.6 31.1 ± 1.0ad 26.0 ± 1.3 28.0 ± 0.9 31.3 ± 1.1ad
Values are means ± SEM. EAA are deﬁned as sum of histidine, isoleucine, methionine, lysine, phenylalanine, threonine, tryptophan and valine; leucine is left out for better
comparison. NEAAare deﬁned as sumof alanine, arginine, asparagine, aspartic acid, glutamic acid, glutamine, glycine and serine. Statistical difference (P< 0.05) from fasted control
at same time point (a), from 60 min within same supplementation group (b), from 75 min within same supplementation group (c) and from leucine at same time point (d).
Fig. 2. Muscle protein synthesis assessed by the SUnSET method and measured in the TA after fasting (F) or supplementation with leucine (L) or leucine-enriched whey protein (W)
at 60, 75 or 90 min after gavage. A) Scatter blot of puromycin-labelled peptides for each condition. Values (means ± SEM) are expressed as a relative ratio to the fasted control group
at 60 min. Statistical difference (P < 0.05) to F within same time (a); to same supplementation vs 60 min gavage (b); to LEU same time (c). B) Representative image of blot stained for
puromycin and Coomassie Blue to verify equal loading of the samples. ‘Bl’ indicates control muscle not treated with puromycin to determine non-speciﬁc background, ‘S’ indicates a
pooled sample of all 60 min Fasted samples used for relative ratio calculations.
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concentrations increased 1.2-fold after supplementation with
WHEY þ LEU compared to fasted at all postprandial times (P < 0.05
vs fasted at same time point) but not after LEU supplementation.
3.2. Serum glucose and insulin concentrations
No changes were observed in glucose concentrations at 60 and
75 min. At 90 min a signiﬁcant decrease was observed with
WHEY þ LEU compared to fasted controls. Serum insulin concen-
trations were signiﬁcantly increased with LEU compared to fasted
mice at all time points (P < 0.05 vs fasted at same time point), while
no signiﬁcant changes were observed with WHEY þ LEU.
3.3. Muscle protein synthesis
LEU gavage had no signiﬁcant effect onMPS after 60 and 75min,
but showed a signiﬁcant decline after 90 min (P ¼ 0.043 vs fasted;
Fig. 2). MPS after supplementation with WHEY þ LEU increased
signiﬁcantly at 60 min compared to fasted control (P ¼ 0.0001 at
60 min; Fig. 2), but returned to fasting level after 75 and 90 min
(P ¼ 0.296 at 75 min and P ¼ 0.285 at 90 min; Fig. 2).
3.4. mTOR signalling proteins
Following LEU supplementation, after 60 min no signiﬁcant
changes were observed in the phosphorylated or total 4E-BP1, Akt
or p70S6k protein (Fig. 3). A signiﬁcant increase in phosphorylated
4E-BP1 was observed with WHEY þ LEU (2.3-fold, P ¼ 0.002 vs
fasted and P ¼ 0.007 vs LEU) while total 4E-BP1 was signiﬁcantly
lower compared to fasted (P ¼ 0.039). This resulted in a signiﬁcant
increase in the phospho-total ratio of 4E-BP1 (P ¼ 0.001 vs fasted,
P ¼ 0.004 vs LEU). Akt phosphorylation was signiﬁcantly higher in
WHEY þ LEU compared to LEU and fasted (1.4-fold, P ¼ 0.037 vs
fasted; P ¼ 0.033 vs LEU; Fig. 3) with no changes in total protein
contents. The phospho-total ratio of Akt was signiﬁcant in
WHEY þ LEU compared to LEU (P ¼ 0.045). Phosphorylation of
p70S6k was signiﬁcantly higher in WHEY þ LEU (P ¼ 0.004 vs
fasted) with no changes in total protein or phospho-total ratio.
4. Discussion
This study showed that administration of a single bolus of
leucine did not increase MPS in aged mice. However, administra-
tion of a bolus of leucine-enriched whey protein with similar
leucine content successfully stimulated MPS. The differential effect
on MPS stimulation was conﬁrmed by phosphorylation of mTOR
signalling pathway proteins. 4E-BP1 and Akt signalling pathway
proteins showed signiﬁcant activation after leucine-enriched whey
protein gavage, but not after leucine administration only.
To our knowledge, this non-response of in vivo MPS to a single
oral bolus of leucine has not been described before in aged animals
or humans. This is in contrast to results in young or adult animals
that show an anabolic response after single leucine supplementa-
tion [8,12,28]. Moreover, in a previous study we also observed that
leucine supplementation reaching similar plasma leucine concen-
trations in adult mice showed a signiﬁcant increase in MPS (un-
published data). Crozier [12] showed that administration of 0.135 g/
kg bw until 1.35 g/kg bw of leucine effectively stimulated MPS in
food-deprived mature rats. This was accompanied by an increase in
4E-BP1 phosphorylation. When comparing adult rats with aged
rats, Dardevet [13] showed that MPS was less responsive to leucine
in epitrochlearis muscle of aged rats, measured in vitro, as
compared to adult rats. This was accompanied by lower p70S6k
activation in muscle of aged rats. In our study, the lack ofpostprandial MPS response in agedmice may be related to anabolic
resistance to leucine and insulin [6,13,29,30]. The likelihood of
anabolic resistance is supported by the fact that there was no rise in
MPS, even though plasma leucine increased ~6-fold and insulin
increased ~3-fold. Therefore, it is not expected that a further in-
crease in the leucine dose would have an additional effect on MPS.
Since no MPS response was observed at 75 and 90 min either, a
delay in MPS response as reported for ageing after anabolic stimuli
[31] is also not likely. The results therefore suggest that leucine
alone, in the absence of elevated levels of amino acids in the
muscle, cannot increase MPS in aged mice [32].
To overcome the lack of available amino acids as precursors to
support de novo protein synthesis, we combined leucine with whey
protein administration, providing a total leucine dose that was like
the leucine gavage alone. Indeed, a signiﬁcant ~1.6-foldMPS increase
was observed after leucine-enriched whey protein that peaked at
60 min and gradually diminished to come back to basal level after
90 min. Leucine has also been studied by others in the context of a
meal or with other amino acids [14e16,18,33,34]. Rieu [14] showed
that a leucine supplemented meal increased postprandial protein
synthesis in aged rats after 10 d of supplementation. Dardevet [15]
showed that aged rats responded to an acute meal only when it
was supplemented with leucine at a dose that doubled the plasma
leucine concentrations. Katsanos [16] reported that, compared to
younger adults, aged subjects needed additional leucine (in an EAA
mixture enriched with 41% leucine) to stimulate protein synthesis.
Magne et al. [33] supplemented aged rats for 40 days with a leucine-
enriched casein diet (containing 44.5 g/kg leucine) showing no effect
on postprandial MPS compared to casein protein. However, whey
protein effectively stimulated postprandial MPS. The authors [33]
described the lack of MPS response with leucine enriched casein as
a desynchronization between the ‘leucine signal’ and the availability
of substrates to inducemuscle protein synthesis.Withwhey protein,
this desynchronization was overcome. Such desynchronization may
explain the difference between leucine alone and leucine-enriched
whey protein in our study. We observed that at 60 min after
leucine-enriched whey protein, plasma and muscle free EAA levels
were higher. While plasma leucine concentrations were not
different, muscle free leucine concentrations were even lower than
after single leucine gavage. The transientMPS response after leucine-
enriched whey protein coincided with a decrease in plasma EAA
levels over time. This argues for the importance of adequate levels of
EAA in addition to leucine to produce a signiﬁcant MPS response.
Moreover, while insulin is considered an anabolic stimulus, serum
insulinwas not increased at 60e90min after leucine-enrichedwhey
gavage. Unfortunately,we cannot exclude that the insulinpeak in the
leucine-enriched whey protein group already occurred before the
60 min time point. In humans receiving a leucine-enriched whey
protein supplement [25,35], insulin peaks at around 30 min after
intake and is back to baseline levels at about 90 min. The lower
glucose levels in the leucine-enriched whey protein group (signiﬁ-
cant at 90 min) may indicate that an insulin-induced glucose
lowering indeed has occurred. In contrast, a high insulin response
was observed within the 60e90 min timeframe after single leucine
gavage. This suggests that leucine-induced insulin is not the exclu-
sive stimulus forMPSbutother signallingpathwaysmaybe involved,
as suggested by others [20,36].
A limitation of our study is that repeated blood sampling is
limited in mice and therefore time-dependent changes in plasma
concentrations of amino acids and insulin cannot be followed in the
same mouse. This could be circumvented in future studies with the
use of dry bloodspots to follow concentrations over time in mice.
Other limitations are that we did not measure other aspects of
protein metabolism, such as protein breakdown, and cannot
discriminate between exogenous and endogenous leucine sources
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Fig. 3. The effect of leucine and leucine-enriched whey protein on activation of 4E-BP1, Akt and p70S6k at 60 min after gavage. F, fasted L, leucine; W, leucine-enriched whey. Values
are means ± SEM. ‘a’ P < 0.05 vs fasted; ‘b’ P < 0.05 vs L.
F.J. Dijk et al. / Clinical Nutrition ESPEN 24 (2018) 127e133132in our study. The increase in plasma EAA after single leucine gavage
at 75 and 90min suggests increased protein breakdown. Finally, the
use of additional control groups, e.g. an isonitrogenous NEAA
control providing equal energy or a whey-only group, could further
substantiate the importance of other amino acids beyond leucine
and the role of leucine for an anabolic response.
A strength of the study is that MPSwasmeasured at three points
over time, which is relevant because a time-dependent increase or
decrease in MPS and a delayed MPS response with advanced age is
known [31,37]. Moreover, we successfully applied the SUnSET
method for measuring MPS in vivo both in fasted and postprandial
conditions. The method is considered a valid and accurate method
for measuring in vivo protein synthesis [38], but its principle of
puromycin-bound peptide formation is different from the ﬂooding
dose method [8,12,15,28,39,40].
The clinical relevance of our data lies in the nutritional support
for leucine-rich or leucine-enriched amino acid mixtures or pro-
teins as most effective to stimulate MPS in older individuals.
Extrapolating to the human situation (e.g. 75 kg male), 5.56 g/kg
bodyweight whey protein (~139 mg) in mice equals 24 g protein in
humans. For leucine, 0.75 g/kg bodyweight (~18.8 mg) in agedmice
represents 3 g leucine [41]. A leucine-enriched whey protein sup-
plement (20 g whey protein, 3 g total leucine) effectively increased
MPS in healthy older adults [25] and increased muscle mass after 3
months of intervention [42]. The PRO-TAGE study group alsorecently published a position paper, recommending the intake of
2.5e2.8 g leucine per meal for older adults [43].
In conclusion, oral administration of leucine-enriched whey
protein stimulates MPS, while administration of leucine only does
not increase MPS in aged mice. We hypothesize that aged mice
require leucine in the presence of other amino acids to induce an
anabolic response. These observations may be relevant for devel-
oping nutritional strategies to stimulate muscle anabolism and
promote muscle mass maintenance with ageing.
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